ArticleNanoscale advances2026
Magnetic field-guided enhancement of nanoparticle uptake and hyperthermia efficacy in 3D tumour models.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic hyperthermia (MH) using iron oxide nanoparticles (MNPs) is a promising cancer treatment strategy, yet its efficacy strongly depends on efficient intracellular nanoparticle delivery. Here, we compared two strategies to enhance MNP uptake by tumour cells: (i) increasing the administered MNP dose and (ii) applying a static magnetic field (MF) gradient to promote nanoparticle-cell interactions and increase availability at the cell surface. Human tumour cell lines, representing distinct challenges for nanoparticle internalisation due to differences in growth behaviour and cellular organisation, were first incubated with glucose-functionalised 11 nm MNPs under two-dimensional (2D) culture conditions to control and quantify intracellular uptake under each strategy. Cells with pre-internalised MNPs were then embedded in collagen-based three-dimensional (3D) tumour models, where MH was applied and therapeutic efficacy was evaluated by confocal microscopy and flow cytometry. While both strategies increased intracellular MNP levels, only MF-assisted internalisation resulted in effective MH-induced cytotoxicity under mild conditions across all tested cell lines. These findings indicate that antitumour MH efficacy is not solely determined by nanoparticle uptake, but also by the strategy used to enhance internalisation, revealing an additional layer of complexity for designing efficient MH protocols.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.